Specialty Drug Distribution
Distributors managing specialty biologic and high-cost drug distribution.
Market snapshot
These figures describe Pharmaceutical & Drug Distribution (5.4.9), the segment that Specialty Drug Distribution sits within — not Specialty Drug Distribution on its own.
- Market size
- ~$1,281B
- Growth
- ~6.6%CAGR (2017–22, nominal)
- Companies
- ~9,960
U.S. Census Bureau 2022 CBP/Economic Census, NAICS 424210 (drugs & druggists' sundries); sales figure is pass-through — distributor margins are very thin.
Business model & economics
Revenue model
Drug resale at very thin margins on enormous volume
Key economics
- Recurring revenue
- High
- EBITDA margin
- Very thin
- Capex intensity
- Low
recurring pharmacy/provider supply
~1–2% gross distribution margins
Characteristics
- An oligopoly of McKesson, Cencora, and Cardinal.
- Razor-thin margins on enormous volume.
- Specialty-pharma distribution the higher-margin growth area.
Geographic concentration
Pharmaceutical and drug distribution clusters in New Jersey — the pharma headquarters belt — with major distribution nodes in Nevada, California, and Hawaii.
U.S. Census Bureau — 2022 County Business Patterns (establishments by state), NAICS 424210. Concentration shown by location quotient.
M&A deal context
Who’s acquiring
- The big-three distribution strategics
- Specialty-pharma distribution acquirers
- Vertical (pharmacy/provider) integrators
What’s driving deals
- Specialty and cold-chain pharma growth.
- Vertical integration with pharmacy and providers.
- Scale and logistics efficiency.
Find Specialty Drug Distribution acquisition targets
Search Acquisera’s index for companies classified under Specialty Drug Distribution (5.4.9.5) and build a targeted deal pipeline.
Search companies